Read the experiences of clinicians and doctors and how Aveir VR Leadless Pacemaker has made an impact in their patients' lives.
Abbott’s Aveir VR Leadless Pacemaker is the next evolution in leadless technology. Approved by the FDA and CMS, Aveir VR Leadless Pacemaker is setting the pace for what’s to come – just ask the experts in the field.
Pioneers Dr. Rahul Doshi, Cardiac Electrophysiologist at Honor Health in Scottsdale, Arizona, and Dr. T. Jared Bunch, Head of Section – Heart Rhythm Services, at the University of Utah Health in Salt Lake City, Utah, recently discussed the technological advantages provided by the Aveir VR Leadless Pacemaker, which Dr. Doshi refers to as “absolutely game-changing technology.”
Two of Aveir VR Leadless Pacemaker’s key design features are its ability to be chronically retrieved and its capabilities for mapping prior to fixation, the experts explain.
“This device is implanted into the myocardium, heart muscle, with a screw, or helix, that is screwed in, and, thus, can be screwed out,” Dr. Doshi explains. “It’s actually designed to be chronically retrieved.”
Drs. Bunch and Doshi also praise the leadless pacemaker’s capabilities for mapping prior to fixation and active fixation design, which allow for more flexibility in where the device is implanted. Because Aveir VR Leadless Pacemaker’s active fixation helix is designed for chronic retrieval and mapping prior to fixation, it helps to reduce the number of repositioning attempts, they explain. This advantageous positioning capability ultimately may result in better long-term outcomes for patients.
“When we implant these devices, they go in a little differently than traditional pacing leads,” says Dr. Bunch. “You are able to map the heart and find your ideal spot to make sure it looks good from where it sits in the heart before anchoring it and screwing it in.”
That mapping capability, Dr. Bunch explains, helps implanters find a better position for placement of the device that is better for the patient long-term, improves battery life, and enhances safety of the procedure.
“Retrieval at the time of procedure, if you need to reposition, is very straightforward,” says Dr. Bunch. “Long-term, it’s critical to recognize that if the system needs to be grabbed, removed, or torqued and removed – retrievability has been very favorable.”
Another game-changing attribute of the Aveir VR Leadless Pacemaker is the increased battery life with a battery capacity that is twice that of currently available leadless pacemakers. Aveir VR Leadless Pacemaker’s long-lasting battery life may lead to fewer procedures, which can help reduce patient risk – a feature that is attractive to both doctors and patients.*
“This is very important, especially for younger patients who require a device, and potentially multiple devices throughout their life span,” says Dr. Doshi. “Being able to replace a device that already lasts a long time will lead to fewer procedures in the future, fewer interventions, and less invasive interventions that actually expose patients to risk.”
Plus, Aveir VR Leadless Pacemaker software is designed for future expandability to a dual chamber system, upon regulatory approval.**
The active fixation design allows more flexibility in where the device is implanted, Dr. Doshi explains.
“If you can imagine the ability to put this device in multiple locations, that could lead to a whole host of advancements,” Dr. Doshi says.
“It completely changes the technology; it’s a game-changer.”
Aveir VR Leadless Pacemaker is three times smaller than the volume of a AAA battery and there is no visibility under the skin, features that make the option especially attractive to patients. And, there are fewer post-implant activity restrictions and fewer lead-related complications.
Watch the full testimonial discussion between Drs. Bunch and Doshi and learn more about Aveir VR Leadless Pacemaker.
*Battery longevity estimates based on projections derived from published technical specifications. Up to twice the projected longevity of current VR leadless pacemakers are based on ISO Standard settings (4.7 yrs Micra ‡ / 10.3 yrs Aveir VR LP: VVIR 60 bpm, 2.5V @0.4 ms, 600 Ω , 100% pacing)
**The LP device electronics are designed to be enabled by future software, upon regulatory approval, to support dual chamber pacing in the future. Dual chamber pacing system is currently in clinical trial (ClinicalTrials.gov NCT #05252702) and limited to investigational use only.
MAT-2211384 v2.0 | Item is approved for US use only